Clinical trial / 2011
Neither aspirin nor resistant starch significantly reduced colorectal polyp counts in young FAP patients.
A multicenter trial randomized 206 young individuals with familial adenomatous polyposis to aspirin (600 mg/day), resistant starch (30 g/day), both, or placebos for 1 to 12 years. Among 133 patients with follow-up endoscopy, neither aspirin (RR = 0.77; 95% CI, 0.54-1.10) nor resistant starch (RR = 1.05; 95% CI, 0.73-1.49) significantly reduced rectal and sigmoid polyp numbers. Aspirin displayed a non-significant trend toward smaller maximum polyp size.
- Study type
- Randomized controlled trial
- Who was studied
- 206 young patients with familial adenomatous polyposis (aged 10-21 years)
- What was measured
- Rectal and sigmoid polyp number and maximum polyp size
THE PAPER
A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis.
Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, Dunlop MG, Eccles D, Ellis A, Evans DG, Fodde R, Maher ER, Möslein G, Vasen HF, Coaker J, Phillips RK, Bülow S, Mathers JC, International CAPP consortium. Cancer Prev Res (Phila), 2011.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.